Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 6

1.

Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension.

Alimajstorovic Z, Westgate CSJ, Jensen RH, Eftekhari S, Mitchell J, Vijay V, Seneviratne SY, Mollan SP, Sinclair AJ.

Eye (Lond). 2020 Jan 2. doi: 10.1038/s41433-019-0751-1. [Epub ahead of print] Review.

PMID:
31896803
2.

Preclinical update on regulation of intracranial pressure in relation to idiopathic intracranial hypertension.

Eftekhari S, Westgate CSJ, Uldall MS, Jensen RH.

Fluids Barriers CNS. 2019 Nov 26;16(1):35. doi: 10.1186/s12987-019-0155-4. Review.

3.

A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics.

O'Reilly MW, Westgate CS, Hornby C, Botfield H, Taylor AE, Markey K, Mitchell JL, Scotton WJ, Mollan SP, Yiangou A, Jenkinson C, Gilligan LC, Sherlock M, Gibney J, Tomlinson JW, Lavery GG, Hodson DJ, Arlt W, Sinclair AJ.

JCI Insight. 2019 Mar 21;4(6). pii: 125348. doi: 10.1172/jci.insight.125348. eCollection 2019 Mar 21.

4.

Free versus total serum 25-hydroxyvitamin D in a murine model of colitis.

Larner DP, Jenkinson C, Chun RF, Westgate CSJ, Adams JS, Hewison M.

J Steroid Biochem Mol Biol. 2019 May;189:204-209. doi: 10.1016/j.jsbmb.2019.01.015. Epub 2019 Jan 30.

PMID:
30710745
5.

Topiramate is more effective than acetazolamide at lowering intracranial pressure.

Scotton WJ, Botfield HF, Westgate CS, Mitchell JL, Yiangou A, Uldall MS, Jensen RH, Sinclair AJ.

Cephalalgia. 2019 Feb;39(2):209-218. doi: 10.1177/0333102418776455. Epub 2018 Jun 13.

6.

A glucagon-like peptide-1 receptor agonist reduces intracranial pressure in a rat model of hydrocephalus.

Botfield HF, Uldall MS, Westgate CSJ, Mitchell JL, Hagen SM, Gonzalez AM, Hodson DJ, Jensen RH, Sinclair AJ.

Sci Transl Med. 2017 Aug 23;9(404). pii: eaan0972. doi: 10.1126/scitranslmed.aan0972.

PMID:
28835515

Supplemental Content

Loading ...
Support Center